LCZ696: a dual-acting sodium supramolecular complex

被引：91

作者：

Feng, Lili ^{[1
]}

Karpinski, Piotr H. ^{[1
]}

Sutton, Paul ^{[1
]}

Liu, Yugang ^{[1
]}

Hook, David F. ^{[2
]}

Hu, Bin ^{[1
]}

Blacklock, Thomas J. ^{[1
]}

Fanwick, Philip E. ^{[3
]}

Prashad, Mahavir ^{[1
]}

Godtfredsen, Sven ^{[1
]}

Ziltener, Christoph ^{[2
]}

机构：

[1] Novartis Pharmaceut, E Hanover, NJ 07936 USA

[2] Novartis Pharma AG, CH-4056 Basel, Switzerland

[3] Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA

来源：

TETRAHEDRON LETTERS | 2012年 / 53卷 / 03期

关键词：

LCZ696; Hypertension; X-ray crystallography; ARNI; Supramolecular complex; INHIBITOR; RECEPTOR; NEPRILYSIN;

D O I：

10.1016/j.tetlet.2011.11.029

中图分类号：

O62 [有机化学];

学科分类号：

070303 [有机化学];

摘要：

LCZ696 displays several surprising features, such as an intrinsic stabilization of the supramolecular complex by monovalent multi-coordinated sodium cations and water molecules. In addition, to the best of our knowledge, the compound is the first example of a dual-acting pharmaceutical built as a supramolecular complex delivering two pharmacologic effects angiotensin receptor 1 (AT1) blockage and neprilysin (NEP) inhibition. (C) 2011 Elsevier Ltd. All rights reserved.

引用

收藏

页码：275 / 276

页数：2

相关论文

共 7 条

[1]

Vasopeptidase inhibition - A double-edged sword? [J].

Campbell, DJ .

HYPERTENSION, 2003, 41 (03) :383-389

[2]

Pharmacokinetics and Pharmacodynamics of LCZ696, a Novel Dual-Acting Angiotensin Receptor-Neprilysin Inhibitor (ARNi) [J].

Gu, Jessie ;

Noe, Adele ;

Chandra, Priya ;

Al-Fayoumi, Suliman ;

Ligueros-Saylan, Monica ;

Sarangapani, Ramesh ;

Maahs, Suzanne ;

Ksander, Gary ;

Rigel, Dean F. ;

Jeng, Arco Y. ;

Lin, Tsu-Han ;

Zheng, Weiyi ;

Dole, William P. .

JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 50 (04) :401-414

[3]

DICARBOXYLIC-ACID DIPEPTIDE NEUTRAL ENDOPEPTIDASE INHIBITORS [J].

KSANDER, GM ;

GHAI, RD ;

DEJESUS, R ;

DIEFENBACHER, CG ;

YUAN, A ;

BERRY, C ;

SAKANE, Y ;

TRAPANI, A .

JOURNAL OF MEDICINAL CHEMISTRY, 1995, 38 (10) :1689-1700

[4]

Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study [J].

Miguel Ruilope, Luis ;

Dukat, Andrej ;

Boehm, Michael ;

Lacourciere, Yves ;

Gong, Jianjian ;

Lefkowitz, Martin P. .

LANCET, 2010, 375 (9722) :1255-1266

[5]

The angiotensin receptor antagonist valsartan: a review of the literature with a focus on clinical trials [J].

Mistry, NB ;

Westheim, AS ;

Kjeldsen, SE .

EXPERT OPINION ON PHARMACOTHERAPY, 2006, 7 (05) :575-581

[6]

Substructure solution with SHELXD [J].

Schneider, TR ;

Sheldrick, GM .

ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY, 2002, 58 :1772-1779

[7]

Mechanism of vasopeptidase inhibitor-induced plasma extravasation: Comparison of omapatrilat and the novel neutral endopeptidase 24.11/angiotensin-converting enzyme inhibitor GW796406 [J].

Sulpizio, AC ;

Pullen, MA ;

Edwards, RM ;

Louttit, JB ;

West, R ;

Brooks, DP .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 315 (03) :1306-1313